Skip to main content

DIMA Biotech

DIMA_Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore,  companies can  have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry. 


www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Human/Mouse/Rat BMP-2 Protein PME30004



The add to cart button will appear once you select the values above

Specifications

50µg

Alternative names:

Bone Morphogenetic Protein 2;BMP-2;Bone Morphogenetic Protein 2A;BMP-2A;BMP2;BMP2A

Description:

Recombinant Human/Mouse/Rat Bone Morphogenetic Protein 2 is produced by our E.coli expression system and the target gene encoding Gln283-Arg396 is expressed.

Background:

Bone Morphogenetic Protein-2 (BMP-2) is one of the bone-growth regulatory factors that belong to the transforming growth factor-beta (TGF-beta) superfamily of proteins. BMPs are synthesized as large precursor molecules, which are cleaved by proteolytic enzymes. The active form of BMP-2 can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.

Molecular characterization:

Not available

Molecular weight:

13.3 KDa

Tag:

Expression host:

E.coli

Target:

BMP-2

Purity:

Greater than 95% as determined by reducing SDS-PAGE.

Formulation / Reconstitution:

Lyophilized from a 0.2 μm filtered solution of 10mM HAc-NH4Ac, 4% D-Mannitol, pH 4.0.

Storage:

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com